PLANO, Texas, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced participation in the upcoming 42nd Annual J.P. Morgan Healthcare Conference to be held in San Francisco from Jan 8-11, 2024. Joseph Dziedzic, President and Chief Executive Officer, is scheduled to present on Wednesday, Jan. 10, 2024, at 4:30 p.m. PT (7:30 p.m. ET).
A live webcast of the presentation will be accessible under “News & Events” on the Investor Relations section of the Integer website at investor.integer.net.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. Integer provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.
| Investor Relations: | Media Relations: |
| Andrew Senn | Kelly Butler |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| 763.951.8312 | 214.618.4216 |
| Last Trade: | US$132.17 |
| Daily Change: | -0.35 -0.26 |
| Daily Volume: | 109,505 |
| Market Cap: | US$4.430B |
October 24, 2024 September 23, 2024 August 22, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
